BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab

Inclusion Criteria: * Be ≥ 18 years of age * Have a life expectancy ≥ 6 weeks * Have a Karnofsky Performance Score (KPS) ≥ 60 * Have pathologically proven GB, gliosarcoma (WHO IV), or anaplastic astrocytoma (WHO III) in recurrence after treatment with bevacizumab * Be at least 14 days from the last administration of bevacizumab * Be at least 28 days from last administration of cytotoxic chemotherapy or other investigational agent * Have received radiation therapy with concurrent temozolomide. Total radiation dosage can range from 5400 to 6000 cGy administered in daily fractions of 150 to 200 cGy over 6 weeks, or the equivalent in a hypofractionated protocol (for example, 4000cGy in 15 fractions or 2500cGy in 5 fractions). Patients who are MGMT negative do not need to have received temozolomide. * Have adequate organ and marrow function as follows (all required): * ANC ≥ 1500 mm3 * Platelets ≥ 100,000/mm3 * Hemoglobin ≥ 9 g/dL * Serum creatinine ≤ 1.8 mg/dL or creatinine clearance \> 50 mL/min Bilirubin ≤ 1.5 mg/dL * Alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) * Aspartate transaminase (AST) ≤ 2.5 x ULN * Prothrombin time (PT) ≤ 1.5 x ULN * International Normalized Ratio (INR) ≤ 1.5 x ULN * Partial thromboplastin time (PTT) ≤ 1.5 x ULN * Subjects of childbearing potential must agree to use hormonal or barrier birth control with spermicidal gel to avoid pregnancy during the study * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Has a history of spontaneous or tumor related cerebral hemorrhage; or has cerebral hemorrhage as determined by the screening FDG PET CT and MRI. This does not include stable post operative blood products seen on a gradient echo MRI sequence. * Has the any of the following cardiac history: * Active heart disease including myocardial infarction within previous 3 months * Symptomatic coronary artery disease * Arrhythmias not controlled by medication * Unstable angina pectoris * Uncontrolled or symptomatic congestive heart failure (NYHA class III and IV) 3.2.3 Uncontrolled or severe coagulopathies or a history of clinically significant bleeding within the past 6 months, including any of the following, but not limited to: * Epistaxis * Hemoptysis * Hematochezia * Hematuria * Gastrointestinal bleeding * Spontaneous or tumor related intracranial hemorrhage * Known predisposition for bleeding such as von Willebrand's disease or other such condition(s) * Uncontrolled concurrent illness that would limit compliance with study requirements, including any of the following, but limited to: * Uncontrolled infection. * Psychiatric illness/social situations * Prior malignancy except for non melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 3 years prior to 1st dose of investigational drug * Receiving any of the following medications: * Therapeutic doses of any anticoagulant, including low molecular weight heparin (LMWH). Concomitant use of warfarin, even at prophylactic doses, is prohibited * Digoxin, digitoxin, lanatoside C, or any type of digitalis alkaloids. * Colony stimulating factors (CSFs) that cannot be held during the monitoring period for dose limiting toxicities (DLT) * Has significant toxicities from prior treatment that have not resolved or stabilized * Known allergy to Coenzyme Q10 * Known allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin K * Is pregnant or lactating * Known to be positive for the human immunodeficiency virus (HIV). Note: HIV testing is not required for eligibility, but if performed previously and was positive, the subject is ineligible.